The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors.
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual's adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells.
Gammaretroviral vectors were the first viral gene-therapy vectors to enter clinical trials and remain in use. One potential hazard associated with the use of such vectors is the presence of replication-competent retroviruses (RCR) in the vector preparations – either as a result of: 1) recombination events between the plasmids used for vector production, 2) interactions between the plasmids and endogenous retroviral sequences in the packaging cell lines, or 3) as a result of contamination in the laboratory.
Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy, radiation therapy, and importantly androgen-deprivation therapy (ADT). Prostate cancer is dependent on androgen hormones, such as testosterone, for sustaining and promoting growth.
NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.
The NCI Laboratory of Molecular Biology is seeking parties interested in licensing a genetically engineered mouse model expressing hMSLN in the thyroid gland for commercialization in the field of cancer therapeutics and research targeting mesothelin-expressing tumors.
The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.
CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.
The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers.
NCI seeks parties interested in licensing to further develop a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias.
The scientists seek co-development parties and/or licensees for a method for measuring low-abundance metabolites in vivo.